Astrazeneca (AZN) Return on Sales (2009 - 2026)

Astrazeneca's Return on Sales history runs 18 years deep, the most recent figure standing at 0.51% for Q1 2026.

• In Q1 2026, Return on Sales rose 5.0% year-over-year to 0.51%; the TTM figure through Mar 2026 stood at 1.27% (up 117.0% YoY), while the FY2025 annual figure was 0.0%, down 7.0% from the prior year.
• Return on Sales was 0.51% for Q1 2026 at Astrazeneca, down from 4.38% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 5.99% in Q2 2024 to a low of 0.02% in Q4 2024.
• Historically, Return on Sales has averaged 1.25% across 5 years, with a median of 0.46% in 2025.
• The sharpest annual moves came in 2024 and 2025: Return on Sales jumped 588 bps in 2024, then sank 208 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.05% in 2022, then tumbled by 34 bps to 0.03% in 2023, then tumbled by 37 bps to 0.02% in 2024, then jumped by 21335 bps to 4.38% in 2025, then sank by 88 bps to 0.51% in 2026.
• The last three Return on Sales figures came in at 0.51% (Q1 2026), 4.38% (Q4 2025), and 2.95% (Q3 2025), per Business Quant data.